Hematopoietic Stem Cell Transplantation for XIAP Deficiency in Japan

Journal of Clinical Immunology

Volumn 37, Issue 1, 2017, Pages 85-91

  Ono, Shintaro ^a   Okano, Tsubasa ^a   Hoshino, Akihiro ^a   Yanagimachi, Masakatsu ^a,b   Hamamoto, Kazuko ^c   Nakazawa, Yozo ^d   Imamura, Toshihiko ^e   Onuma, Masaei ^f   Niizuma, Hidetaka ^g   Sasahara, Yoji ^g   Tsujimoto, Hiroshi ^h   Wada, Taizo ⁱ   Kunisaki, Reiko ^j   Takagi, Masatoshi ^a   Imai, Kohsuke ^a   Morio, Tomohiro ^a   Kanegane, Hirokazu ^a  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^b YOKOHAMA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c ATOMIC BOMB SURVIVORS HOSPITAL   (Japan)

^d SHINSHU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^e KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^f Miyagi Childrens Hospital   (Japan)

^g TOHOKU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^h WAKAYAMA MEDICAL UNIVERSITY   (Japan)

ⁱ KANAZAWA UNIVERSITY   (Japan)

^j YOKOHAMA CITY UNIVERSITY MEDICAL CENTER   (Japan)

more..

Author keywords

Hematopoietic stem cell transplantation; hemophagocytic lymphohistiocytosis; inflammatory bowel disease; reduced intensity conditioning; X linked lymphoproliferative syndrome; XIAP deficiency

Indexed keywords

CYCLOPHOSPHAMIDE; ETOPOSIDE; FLUDARABINE; MELPHALAN; METHOTREXATE; PHOSPHODIESTERASE INHIBITOR; TACROLIMUS; THYMOCYTE ANTIBODY; X LINKED INHIBITOR OF APOPTOSIS; XIAP PROTEIN, HUMAN;

ACUTE GRAFT VERSUS HOST DISEASE; ADULT RESPIRATORY DISTRESS SYNDROME; ARTICLE; BK VIRUS; CHILD; CLINICAL ARTICLE; COLONOSCOPY; CYTOMEGALOVIRUS; ENGRAFTMENT SYNDROME; GRAFT FAILURE; GRAFT VERSUS HOST REACTION; HEALTH CARE SURVEY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMOPHAGOCYTIC SYNDROME; HUMAN; HUMAN HERPESVIRUS 6; INFANT; JAPAN; JC VIRUS; LYMPH NODE IRRADIATION; OUTCOME ASSESSMENT; PLASMA EXCHANGE; PRESCHOOL CHILD; PRIORITY JOURNAL; PROPHYLAXIS; PROTEIN DEFICIENCY; PULMONARY HYPERTENSION; QUESTIONNAIRE; REDUCED INTENSITY CONDITIONING; REMISSION; SCHOOL CHILD; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT RESPONSE; VIRUS INFECTION; VIRUS REACTIVATION; X LINKED INHIBITOR OF APOPTOSIS PROTEIN DEFICIENCY; ALLOTRANSPLANTATION; AMINO ACID SUBSTITUTION; CODON; DEFICIENCY; GENETICS; IMMUNE DEFICIENCY; MORTALITY; MUTATION; PROCEDURES; SURVIVAL ANALYSIS; TRANSPLANTATION CONDITIONING; TREATMENT OUTCOME;

AMINO ACID SUBSTITUTION; CODON; GRAFT VS HOST DISEASE; HEALTH CARE SURVEYS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOLOGIC DEFICIENCY SYNDROMES; JAPAN; LYMPHOHISTIOCYTOSIS, HEMOPHAGOCYTIC; MUTATION; SURVIVAL ANALYSIS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; X-LINKED INHIBITOR OF APOPTOSIS PROTEIN;

EID: 84994330738     PISSN: 02719142     EISSN: 15732592     Source Type: Journal    
DOI: 10.1007/s10875-016-0348-4     Document Type: Article

References (32)

1. Sumegi J, Huang D, Lanyi A, Davis JD, Seemayer TA, Maeda A, et al. Correlation of mutations of the SH2D1A gene and Epstein-Barr virus infection with clinical phenotype and outcome in X-linked lymphoproliferative disease. Blood. 2000;96:3118–25.
2. Seemayer TA, Gross TG, Egeler RM, Pirruccello SJ, Davis JR, Kelly CM, et al. X-linked lymphoproliferative disease: twenty-five years after the discovery. Pediatr Res. 1995;38:471–8.
3. Tangye SG. XLP: clinical features and molecular etiology due to mutations in SH2D1A encoding SAP. J Clin Immunol. 2014;34:772–9.
4. Coffey AJ, Brooksbank RA, Brandau O, Oohashi T, Howell GR, Bye JM, et al. Host response to EBV infection in X-linked lymphoproliferative disease results from mutations in an SH2-domain encoding gene. Nat Genet. 1998;20:129–35.
5. Nichols KE, Harkin DP, Levitz S, Krainer M, Kolquist KA, Genovese C, et al. Inactivating mutations in an SH2 domain-encoding gene in X-linked lymphoproliferative syndrome. Proc Natl Acad Sci U S A. 1998;95:13765–70.
6. Sayos J, Wu C, Morra M, Wang N, Zhang X, Allen D, et al. The X-linked lymphoproliferative-disease gene product SAP regulates signals induced through the co-receptor SLAM. Nature. 1998;395:462–9.
7. Rigaud S, Fondanèche MC, Lambert N, Pasquier B, Mateo V, Soulas P, et al. XIAP deficiency in humans causes an X-linked lymphoproliferative syndrome. Nature. 2006;444:110–4.
8. Eckelman BP, Salvesen GS, Scott FL. Human inhibitor of apoptosis proteins: why XIAP is the black sheep of the family. EMBO Rep. 2006;10:988–94.
9. Filipovich AH, Zhang K, Snow AL, Marsh RA. X-linked lymphoproliferative syndromes: brothers or distant cousins. Blood. 2010;116:3398–408.
10. Rezaei N, Mahmoudi E, Aghamohammadi A, Das R, Nichols KE. X-linked lymphoproliferative syndrome: a genetic condition typified by the triad of infection, immunodeficiency and lymphoma. Br J Haematol. 2011;152:13–30.
11. Worthey EA, Mayer AN, Syverson GD, Helbling D, Bonacci BB, Decker B, et al. Making a definitive diagnosis: successful clinical application of whole exome sequencing in a child with intractable inflammatory bowel disease. Genet Med. 2011;13:255–62.
12. Hugot JP, Chamaillard M, Zouali H, Lesage S, Cezard JP, Belaiche J, et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn’s disease. Nature. 2001;411:599–603.
13. Jostins L, Ripke S, Weersma RK, Duerr RH, McGovern DP, Hui KY, et al. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature. 2012;491:119–24.
14. Marsh RA, Bleesing JJ, Chandrakasan S, Jordan MB, Davies SM, Filipovich AH. Reduced-intensity conditioning hematopoietic cell transplantation is an effective treatment for patients with SLAM-associated protein deficiency/X-linked lymphoproliferative Disease type 1. Biol Blood Marrow Transplant. 2014;20:1641–5.
15. Marsh RA, Rao K, Satwani P, Lehmberg K, Müller I, Li D, et al. Allogeneic hematopoietic cell transplantation for XIAP deficiency: an international survey reveals poor outcomes. Blood. 2013;121:877–83.
16. Yang X, Kanegane H, Nishida N, Imamura T, Hamamoto K, Miyashita R, et al. Clinical and genetic characteristics of XIAP deficiency in Japan. J Clin Immunol. 2012;32:411–20.
17. Wada T, Kanegane H, Ohta K, Ohta K, Katoh F, Imamura T, et al. Sustained elevation of serum interleukin-18 and its association with hemophagocytic lymphohistiocytosis in XIAP deficiency. Cytokine. 2014;65:74–8.
18. Yang X, Hoshino A, Taga T, Kunitsu T, Ikeda Y, Yasumi T, et al. A female patient with incomplete hemophagocytic lymphohistiocytosis caused by a heterozygous XIAP mutation associated with non-random X-chromosome inactivation skewed towards the wild-type XIAP allele. J Clin Immunol. 2015;35:244–8.
19. Tsuma Y, Imamura T, Ichise E, Sakamoto K, Ouchi K, Osone S, et al. Successful treatment of idiopathic colitis related to XIAP deficiency with allo-HSCT using reduced-intensity conditioning. Pediatr Transplant. 2015;19:E25–8.
20. Rondon G, Saliba RM, Khouri I, Giralt S, Chan K, Jabbour E, et al. Long-term followup of patients who experienced graft failure postallogeneic progenitor cell transplantation. Results of a single institution analysis. Biol Blood Marrow Transplant. 2008;14:859–66.
21. Fleischhauer K, Locatelli F, Zecca M, Orofino MG, Giardini C, De Stefano P, et al. Graft rejection after unrelated donor hematopoietic stem cell transplantation for thalassemia is associated with nonpermissive HLA-DPB1 disparity in host-versus graft direction. Blood. 2006;107:2984–92.
22. Hamidieh AA, Pourpak Z, Hosseinzadeh M, Fazlollahi MR, Alimoghaddam K, Movahedi M, et al. Reduced-intensity conditioning hematopoietic SCT for pediatric patients with LAD-1: clinical efficacy and importance of chimerism. Bone Marrow Transplant. 2012;47:646–50.
23. Bacigalupo A, Ballen K, Rizzo D, Giralt S, Lazarus H, Ho V, et al. Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transplant. 2009;15:1628–33.
24. Glucksberg H, Storb R, Fefer A, Buckner CD, Neiman PE, Clift RA, et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HLA-matched sibling donors. Transplantation. 1974;18:295–304.
25. Shulman HM, Sale GE, Lerner KG, Barker EA, Weiden PL, Sullivan K, et al. Chronic cutaneous graft-versus-host disease in man. Am J Pathol. 1978;91:545–70.
26. Aguilar C, Latour S. X-linked inhibitor of apoptosis protein deficiency: more than an X-linked lymphoproliferative syndrome. J Clin Immunol. 2015;35:331–8.
27. Worth AJ, Nikolajeva O, Chiesa R, Rao K, Veys P, Amrolia PJ. Successful stem cell transplant with antibody-based conditioning for XIAP deficiency with refractory hemophagocytic lymphohistiocytosis. Blood. 2013;121:4966–8.
28. Chellapandian D, Krueger J, Schechter T, et al. Successful allogeneic hematopoietic stem cell transplantation in XIAP deficiency using reduced-intensity conditioning. Pediatr Blood Cancer. 2016;63:355–7.
29. Nishiwaki S, Nakayama T, Murata M, Nishida T, Sugimoto K, Saito S, et al. Dexamethasone palmitate successfully attenuates hemophagocytic syndrome after allogeneic stem cell transplantation: macrophage-targeted steroid therapy. Int J Hematol. 2012;95:428–33.
30. Kobayashi R, Tanaka J, Hashino S, Ota S, Torimoto Y, Kakinoki Y, et al. Etoposide-containing conditioning regimen reduces the occurrence of hemophagocytic lymphohistiocytosis after SCT. Bone Marrow Transplant. 2014;49:254–7.
31. Rowan WC, Hale G, Tite JP, Brett SJ. Cross-linking of the CAMPATH-1 antigen (CD52) triggers activation of normal human T lymphocytes. Int Immunol. 1995;7:69–77.
32. Engelhardt KR, Shah N, Faizura-yeop I, Kocacik Uygun DF, Frede N, Muise AM, et al. Clinical outcome in IL-10- and IL-10 receptor-deficient patients with or without hematopoietic stem cell transplantation. J Allergy Clin Immunol. 2013;131:825–30.